CDA: Combinatorial Drug Discovery Using Transcriptional Response Modules
暂无分享,去创建一个
Kyoung Mii Park | Ji‐Hyun Lee | Dae Kim | Taejung Bae | Kyoohyoung Rho | Ji-Tea Kim | Jong-Jun Lee | Yeongjun Jang | Byung-Cheol Kim | Sunghoon Kim | Ji Hyun Lee | Jong-Jun Lee | K. Park
[1] S D Kemp,et al. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. , 1995, Science.
[2] J C Reed,et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. , 1998, Cancer research.
[3] W. Moolenaar. Bioactive lysophospholipids and their G protein-coupled receptors. , 1999, Experimental cell research.
[4] J. Chun,et al. Lysophosphatidic acid receptors. , 2000, Molecular pharmacology.
[5] P. Goss,et al. Estrogen and the risk of breast cancer. , 2001, The New England journal of medicine.
[6] Ioannis Xenarios,et al. DIP: The Database of Interacting Proteins: 2001 update , 2001, Nucleic Acids Res..
[7] A. Ullrich,et al. Molecular targets for breast cancer therapy and prevention , 2001, Nature Medicine.
[8] G. Berx,et al. The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression , 2001, Breast Cancer Research.
[9] R. Bianco,et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. , 2001, Cancer research.
[10] H. Nelson,et al. Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma. , 2001, The Journal of allergy and clinical immunology.
[11] Eric K. Gupta,et al. Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia. , 2002, Heart disease.
[12] M. Campiglio,et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] H. Kubinyi. Drug research: myths, hype and reality , 2003, Nature Reviews Drug Discovery.
[14] Adrian V. Lee,et al. Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. , 2003, Cancer research.
[15] Conrad Kunick,et al. Alsterpaullone, a novel cyclin‐dependent kinase inhibitor, induces apoptosis by activation of caspase‐9 due to perturbation in mitochondrial membrane potential , 2003, Molecular carcinogenesis.
[16] Adam J. Smith,et al. The Database of Interacting Proteins: 2004 update , 2004, Nucleic Acids Res..
[17] N. Campbell. Genetic association database , 2004, Nature Reviews Genetics.
[18] M. Jordan,et al. Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.
[19] T. Ashburn,et al. Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.
[20] J. Stelling,et al. Robustness of Cellular Functions , 2004, Cell.
[21] Dan Xu,et al. Specific Cleavage of Mcl-1 by Caspase-3 in Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis in Jurkat Leukemia T Cells* , 2005, Journal of Biological Chemistry.
[22] M. Hung,et al. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization , 2006, Breast Cancer Research and Treatment.
[23] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[24] Hiroshi Suzuki,et al. Lysophosphatidic receptor, LPA3, is positively and negatively regulated by progesterone and estrogen in the mouse uterus. , 2006, Life sciences.
[25] Keith T Flaherty,et al. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases , 2006, Molecular Cancer Therapeutics.
[26] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[27] Qiang Wang,et al. ErbB receptors: from oncogenes to targeted cancer therapies. , 2007, The Journal of clinical investigation.
[28] Tatiana A. Tatusova,et al. Entrez Gene: gene-centered information at NCBI , 2004, Nucleic Acids Res..
[29] H. Kitano. A robustness-based approach to systems-oriented drug design , 2007, Nature Reviews Drug Discovery.
[30] G. Hampton,et al. Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole , 2007, Pharmacogenetics and genomics.
[31] Martin Serrano,et al. Nucleic Acids Research Advance Access published October 18, 2007 ChemBank: a small-molecule screening and , 2007 .
[32] Todd R Golub,et al. Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation , 2008, Proceedings of the National Academy of Sciences.
[33] Soon-ja Kim,et al. Histone deacetylase inhibitor scriptaid induces cell cycle arrest and epigenetic change in colon cancer cells. , 2008, International journal of oncology.
[34] R. García-Becerra,et al. Regulation of LPA receptor function by estrogens. , 2008, Biochimica et biophysica acta.
[35] Biyun Wang,et al. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy. , 2008, Oral oncology.
[36] C. Sander,et al. Models from experiments: combinatorial drug perturbations of cancer cells , 2008, Molecular systems biology.
[37] P. Bork,et al. Drug Target Identification Using Side-Effect Similarity , 2008, Science.
[38] Guanghui Hu,et al. Human Disease-Drug Network Based on Genomic Expression Profiles , 2009, PloS one.
[39] N Harbeck,et al. Triple-negative breast cancer--current status and future directions. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] Albert-László Barabási,et al. A Dynamic Network Approach for the Study of Human Phenotypes , 2009, PLoS Comput. Biol..
[41] Olivier Bouchaud,et al. Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base , 2009, Malaria Journal.
[42] Xiaohua Ma,et al. Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.
[43] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[44] Russ B. Altman,et al. Pharmacogenomics and bioinformatics: PharmGKB. , 2010, Pharmacogenomics.
[45] Jeremy E Purvis,et al. Pairwise agonist scanning predicts cellular signaling responses to combinatorial stimuli , 2010, Nature Biotechnology.
[46] S. Marsh,et al. Irinotecan pharmacogenomics. , 2010, Pharmacogenomics.
[47] U. Alon,et al. Protein Dynamics in Drug Combinations: a Linear Superposition of Individual-Drug Responses , 2010, Cell.
[48] Ronald Simon,et al. Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis. , 2010, The American journal of pathology.
[49] Yihong Ma,et al. Histone Deacetylase Inhibitors Downregulate Checkpoint Kinase 1 Expression to Induce Cell Death in Non-Small Cell Lung Cancer Cells , 2010, PloS one.
[50] Xing-Ming Zhao,et al. A systems biology approach to identify effective cocktail drugs , 2010, BMC Systems Biology.
[51] A. Sapino,et al. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib , 2011, Breast Cancer Research and Treatment.
[52] Lu Huang,et al. Update of TTD: Therapeutic Target Database , 2009, Nucleic Acids Res..
[53] Hua He,et al. Candidate genes influencing sensitivity and resistance of human glioblastoma to Semustine , 2011, Brain Research Bulletin.
[54] Lin He,et al. Exploring Off-Targets and Off-Systems for Adverse Drug Reactions via Chemical-Protein Interactome — Clozapine-Induced Agranulocytosis as a Case Study , 2011, PLoS Comput. Biol..
[55] J. Croxtall,et al. Fulvestrant , 2011, Drugs.
[56] Thomas C. Wiegers,et al. The Comparative Toxicogenomics Database: update 2011 , 2010, Nucleic Acids Res..
[57] Xing-Ming Zhao,et al. Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data , 2011, PLoS Comput. Biol..
[58] Livia Perfetto,et al. MINT, the molecular interaction database: 2012 update , 2011, Nucleic Acids Res..